BRPI0412477A - aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos - Google Patents

aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos

Info

Publication number
BRPI0412477A
BRPI0412477A BRPI0412477-4A BRPI0412477A BRPI0412477A BR PI0412477 A BRPI0412477 A BR PI0412477A BR PI0412477 A BRPI0412477 A BR PI0412477A BR PI0412477 A BRPI0412477 A BR PI0412477A
Authority
BR
Brazil
Prior art keywords
polypeptides
beta
recombinant human
human interferon
present
Prior art date
Application number
BRPI0412477-4A
Other languages
English (en)
Inventor
Eirik Nestass
Erno Pungor
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0412477A publication Critical patent/BRPI0412477A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"APERFEIçOADOS POLIPEPTìDEOS DE INTERFERON-BETA-1B RECOMBINANTES HUMANOS". A presente invenção refere-se a polipeptídeos de interferonbeta-1b ('IFN-<225>-1b') recombinante humano, ou fragmentos, análogos, derivados ou variantes dos mesmos, que apresentam uma aperfeiçoada atividade específica. A presente invenção também refere-se a composições farmacêuticas compreendendo tais polipeptídeos IFN-<225>-1b, ou fragmentos, análogos, derivados ou variantes dos mesmos, de utilidade para o tratamento de esclerose múltipla. A presente invenção refere-se ainda a métodos de produção de composições de 1FN-<225>-1b.
BRPI0412477-4A 2003-07-11 2004-07-06 aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos BRPI0412477A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48665703P 2003-07-11 2003-07-11
PCT/US2004/021618 WO2005016371A1 (en) 2003-07-11 2004-07-06 IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES

Publications (1)

Publication Number Publication Date
BRPI0412477A true BRPI0412477A (pt) 2006-09-19

Family

ID=34193062

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412477-4A BRPI0412477A (pt) 2003-07-11 2004-07-06 aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos

Country Status (15)

Country Link
US (1) US20050008616A1 (pt)
EP (1) EP1646397B1 (pt)
JP (1) JP2007530419A (pt)
KR (1) KR20060034286A (pt)
CN (1) CN100408090C (pt)
AU (1) AU2004264855A1 (pt)
BR (1) BRPI0412477A (pt)
CA (1) CA2528514A1 (pt)
ES (1) ES2393783T3 (pt)
IL (2) IL172269A0 (pt)
MX (1) MXPA06000460A (pt)
NO (1) NO20060675L (pt)
RU (1) RU2006104023A (pt)
WO (1) WO2005016371A1 (pt)
ZA (1) ZA200601236B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786917A4 (en) * 2004-07-26 2008-05-28 Enzon Pharmaceuticals Inc OPTIMIZED INTERFERON BETA-GEN
JP5208733B2 (ja) 2005-06-29 2013-06-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 組換えインターフェロンα２（ＩＦＮα２）変異体
EP2581450B1 (en) 2006-05-02 2018-08-15 MedImmune Limited Non-natural amino acid substituted polypeptides
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
CN103898123B (zh) * 2012-12-28 2019-03-15 北京韩美药品有限公司 重组人IFN-β-1a及其生产和纯化方法
CN108841793B (zh) * 2018-06-08 2021-08-27 东北农业大学 抗鸭Mx-A单克隆抗体及其在检测鸭Mx蛋白的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano

Also Published As

Publication number Publication date
NO20060675L (no) 2006-04-06
ES2393783T3 (es) 2012-12-28
JP2007530419A (ja) 2007-11-01
CN1822852A (zh) 2006-08-23
KR20060034286A (ko) 2006-04-21
IL207422A0 (en) 2010-12-30
IL172269A0 (en) 2006-04-10
EP1646397B1 (en) 2012-08-22
EP1646397A1 (en) 2006-04-19
CN100408090C (zh) 2008-08-06
MXPA06000460A (es) 2006-04-07
AU2004264855A1 (en) 2005-02-24
WO2005016371A8 (en) 2006-06-15
CA2528514A1 (en) 2005-02-24
ZA200601236B (en) 2007-05-30
WO2005016371A1 (en) 2005-02-24
US20050008616A1 (en) 2005-01-13
RU2006104023A (ru) 2006-07-27

Similar Documents

Publication Publication Date Title
IL199914A0 (en) Further use of protein kinase n beta
SE0301010D0 (sv) Novel compounds
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
EP2085096A3 (en) Novel composition and methods for the treatment of immune related diseases
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
SE0301009D0 (sv) Novel compounds
BR0112666A (pt) Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
GEP20074197B (en) 5ht2c receptor modulators
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
GB0129260D0 (en) Pharmaceutical compositions and their uses
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
SI1696905T1 (sl) Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
EP0975351A4 (en) TREATMENT OF MULTIPLE Sclerosis BY TAKING OR INHALING COPOLYMER-1
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
NZ516506A (en) Interleukin-5 inhibiting 6-azauracil derivatives
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
BR0210401A (pt) Composto, composição farmacêutica, uso de um composto e método para o tratamento de um distúrbio ou de uma doença de um corpo de animal vivo, incluindo um humano
MXPA06000460A (es) Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b.
AU2003251728A8 (en) Placental growth factor as a target for the treatment of osteoporosis
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.